Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02185599
Other study ID # IMPROVE-100
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2014
Est. completion date October 9, 2017

Study information

Verified date March 2020
Source DySIS Medical Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study will observe and quantify shifts in colposcopy practice and outcome improvements in U.S. community-based cervical screening colposcopy examinations after the introduction of the DySIS colposcope with Advanced Cervical Scan.

The study will collect colposcopy data across multiple sites in two arms; a prospective arm, with DySIS being used for the examination and a retrospective arm, with data retrieved from patient charts.


Description:

Each site will contribute data to both arms; the study will collect data on demographics, disease yield, number of biopsies and treatment decisions. Study subjects will receive standard of care procedures and management.

Prospective data will be collected at colposcopy examinations performed using the DySIS digital colposcope on consecutive patients that have been referred for colposcopy after a positive screening test. Retrospective data on colposcopy examinations performed using a standard colposcope will be collected from patient medical records, to capture standard practice to-date as a control for comparisons. The retrospective data will be collected from consecutive examinations performed by the providers participating in the prospective arm and for the preceding year.


Recruitment information / eligibility

Status Completed
Enrollment 7555
Est. completion date October 9, 2017
Est. primary completion date October 9, 2017
Accepts healthy volunteers No
Gender Female
Age group 21 Years and older
Eligibility Inclusion Criteria:

1. Females 21 years or older

2. Able to give informed consent

3. Referred for colposcopy with a screening test result that indicates the need for a colposcopy, based on guidelines and practice:

- HSIL, ASC-H, LSIL cytology

- 2x ASC-US cytology (25 or above)

- 2x/3x LSIL/ASC-US cytology (21-24)

- ASC-US pap and hrHPV cotest/reflex

- HPV 16/18 primary screening (=25)

- ASC-US pap after hrHPV

- hrHPV x2 (=30)

- HPV16 or 16 after negative cytology/hrHPV (=30)

- Follow-up of CIN2/3 biopsy (younger women)

- hrHPV and/or =ASC-US pap post-excision

Exclusion Criteria:

1. Previous hysterectomy, previous/current chemotherapy, radiation treatment for cervical neoplasia or other concurrent cancer

2. Pregnancy

3. Known human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)

4. Referred for vulva/vaginal disease

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DySIS
Colposcopy performed with the DySIS digital colposcope

Locations

Country Name City State
United States Unified Women's Clinical research-Alpharetta Alpharetta Georgia
United States Unified Women's Clinical Research-Atlanta Atlanta Georgia
United States Austin Area OB-Gyn Austin Texas
United States Dr Gregory Shifrin, OB/GYN, PC Brooklyn New York
United States Unified Women's Clinical Research-Cary Cary North Carolina
United States OB-GYN Associates Cedar Rapids Iowa
United States Advocate Illinois Masonic Medical Center - Creticos Cancer Center Chicago Illinois
United States Nye Partners in Women's Health Chicago Illinois
United States Coastal Bend Women's center Corpus Christi Texas
United States The Women's Center at Southview Dayton Ohio
United States Midwest Center for Women's Healthcare Elgin Illinois
United States Advanced Women's Healthcare Specialists, SC Elk Grove Village Illinois
United States Providea Health Partners, LLC Evergreen Park Illinois
United States Brodsky & Taylor, PLC Ferndale Michigan
United States Laura Bradford, MD Fort Worth Texas
United States Northeast Georgia Physicians Group- Heritage Gainesville Georgia
United States Unified Women's Clinical Research-Gainesville Gainesville Florida
United States Unified Women's Clinical Research- Central Carolina Greensboro North Carolina
United States Unified Women's Clinical Research-Greensboro Greensboro North Carolina
United States NJ Gynecological Institute Hackensack New Jersey
United States Women's Wellness World Hazel Crest Illinois
United States Lakeside Ob/Gyn-Northeast Georgia Physician Group Hoschton Georgia
United States Margaret A. Smollen, MD, PC Iowa City Iowa
United States Las Colinas OBGyn Irving Texas
United States MacArthur OB/GYN Irving Texas
United States North Florida OB GYN Associates, PA Jacksonville Florida
United States Advanced Women's Wellness Katy Texas
United States Osceola Ob-Gyn, PA Kissimmee Florida
United States Zeid Women's Health Center Longview Texas
United States Craig Ranch Ob/Gyn McKinney Texas
United States Women's Healthcare of Illinois Mokena Illinois
United States Lyndhurst Clinical Research- Mt Airy Mount Airy North Carolina
United States The Advanced Gynecologic Surgery Institute Naperville Illinois
United States Women's Center for Health Naperville Illinois
United States Southwest Women's Healthcare Associates Olympia Fields Illinois
United States Women's Healthcare of Princeton, LLC Princeton New Jersey
United States Advanced Ob-Gyn Associates Richardson Texas
United States Piedmont Preferred Women's Healthcare Associates Ridgeway Virginia
United States Dr DeLeon's Women's Healthcare Rowlett Texas
United States Arizona Oncology Scottsdale Arizona
United States New Beginnings, OB/GYN Springfield New Jersey
United States Physicians & Surgeons for Women, Inc Springfield Ohio
United States The University of Toledo Toledo Ohio
United States Downriver Obstetrics & Gynecology Trenton Michigan
United States Hinsdale & Oak Brook Women's Clinic Willowbrook Illinois
United States Lyndhurst Clinical Research Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
DySIS Medical Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects diagnosed with CIN2+ cervical lesions Changes in number of subjects diagnosed with CIN2+ cervical lesions At time of colposcopy
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03196180 - Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Early Phase 1
Recruiting NCT05074264 - Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico N/A
Recruiting NCT02406352 - Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia N/A
Completed NCT02529930 - An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) Phase 1/Phase 2